E*Trade’s CEO departs as Citadel injects $2.5bn into the firm

E*Trade’s chief executive, Mitchell Caplan, is the latest high-profile casualty of the US subprime crisis. Jarrett Lilien, the financial services firm’s president, has been named acting chief executive.

E*Trade announced it will search for a permanent replacement, and will consider Lilien among the candidates.

This follows the stepping down of both Merrill Lynch and Citi’s chief executives over the past month, as firms shake up their management teams after suffering losses from the credit crisis.

Citadel will purchase E*Trade’s entire asset-backed securities (ABS) portfolio in a deal worth $2.5 billion. This transaction removes the assets with the greatest market risk from the firm's consolidated balance sheet. E*Trade said the deal would allow the company to focus on its core retail business, and would provide additional capital to manage credit risk.

"This transaction with Citadel is not only a major vote of confidence from one of the world's leading financial institutions, but also allows us to directly address customer concerns and get back to our real business, which is providing industry-leading products and services to our customers," said Lilien.

E*Trade had seen continued declines in the fair value of its $3 billion asset-backed securities portfolio, predominantly within ABS collateralised debt obligations (CDO) and second-lien securities. The total exposure to ABS CDO and second-lien securities on September 30, 2007 was approximately $450 million in amortised cost, including about $50 million of AAA-rated asset-backed CDOs that were downgraded to below investment grade. The company stated it expected the declines in fair value to result in further securities writedowns in the fourth quarter.

See also:
Change at top as Citi sees writedowns
O'Neal 'retires' as Merrill CEO after $8 billion writedown

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here